CD79B Antibody (SN8): sc-18902
- CD79B Antibody (SN8) is a mouse monoclonal IgG1 κ, cited in 2 publications, provided at 200 µg/ml
- raised against cell membranes from B-prolymphocytic leukemia cells of human origin
- recommended for detection of the extracellular portion of CD79B of human origin by WB, IP, IF and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- m-IgG Fc BP-HRP, m-IgG1 BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for CD79B Antibody (SN8) for WB applications. These reagents are now offered in bundles with CD79B Antibody (SN8) (see ordering information below).
QUICK LINKS
CD79B Antibody (SN8) is a mouse monoclonal IgG1 antibody that detects CD79B in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD79B, also known as B29, plays a crucial role in the immune response as a component of the B cell antigen receptor complex, which is essential for B cell activation and signaling. CD79B is primarily located on the surface of B cells, where CD79B associates with membrane immunoglobulin, such as IgM or IgD, to facilitate antigen recognition and presentation. The interaction between CD79B and these immunoglobulins is vital for proper B cell functioning, enabling effective pathogen response. Additionally, CD79B′s cytoplasmic tail contains an immuno-receptor tyrosine-based activation motif (ITAM), which is critical for initiating downstream signaling pathways that lead to B cell activation and proliferation. Anti-CD79B antibody (SN8) enables valuable insights into B cell biology and immune response mechanisms.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD79B Antibody (SN8) References:
- Alternative splicing of CD79a (Ig alpha) and CD79b (Ig beta) transcripts in human B-CLL cells. | Alfarano, A., et al. 1999. Curr Top Microbiol Immunol. 246: 241-6; discussion 247-8. PMID: 10396062
- CD79b expression in chronic lymphocytic leukemia. Association with trisomy 12 and atypical immunophenotype. | Schlette, E., et al. 2003. Arch Pathol Lab Med. 127: 561-6. PMID: 12708898
- CD79B and MYD88 mutations in diffuse large B-cell lymphoma. | Kim, Y., et al. 2014. Hum Pathol. 45: 556-64. PMID: 24444466
- MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. | Takeuchi, T., et al. 2017. Cancer. 123: 1166-1173. PMID: 27915469
- Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas. | Ding, S., et al. 2020. Target Oncol. 15: 365-375. PMID: 32495161
- Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma. | Bourbon, E. and Salles, G. 2020. Expert Opin Investig Drugs. 29: 1079-1088. PMID: 32700972
- Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma. | Camus, V. and Tilly, H. 2021. Future Oncol. 17: 127-135. PMID: 32954807
- Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice. | Visco, C., et al. 2020. Cancers (Basel). 12: PMID: 33050534
- B-cell modulation with anti-CD79b antibodies ameliorates experimental autoimmune encephalitis in mice. | Renner, K., et al. 2022. Eur J Immunol. 52: 656-668. PMID: 34962287
- Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression. | Huse, K., et al. 2022. J Immunol. 209: 2042-2053. PMID: 36426942
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD79B Antibody (SN8) | sc-18902 | 200 µg/ml | $322.00 | |||
CD79B Antibody (SN8): m-IgG Fc BP-HRP Bundle | sc-536612 | 200 µg Ab; 10 µg BP | $361.00 | |||
CD79B Antibody (SN8): m-IgGκ BP-HRP Bundle | sc-533768 | 200 µg Ab; 40 µg BP | $361.00 | |||
CD79B Antibody (SN8): m-IgG1 BP-HRP Bundle | sc-544707 | 200 µg Ab; 20 µg BP | $361.00 | |||
CD79B Antibody (SN8) FITC | sc-18902 FITC | 200 µg/ml | $336.00 | |||
CD79B Antibody (SN8) PE | sc-18902 PE | 200 µg/ml | $349.00 |